Kiniksa trial of mavrilimumab in COVID-19-related ARDS misses goal

Bermuda-based Kiniksa Pharmaceuticals (Nasdaq: KNSA) saw its shares drop more than 15% after it announced that the Phase III portion of the Phase II/III trial of mavrilimumab in COVID-19-related acute respiratory syndrome (ARDS) did not meet the primary efficacy endpoint.

Mavrilimumab is an investigational fully human monoclonal antibody (MAb) that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα).

“The Phase III study of mavrilimumab in COVID-19-related ARDS did not provide the expected outcome, however we are proud of our efforts to help patients in need during this unprecedented time. We greatly appreciate the participation of the patients, their families, the investigators, and the Kiniksa employees who made this study possible,” said Sanj Patel, chairman and chief executive of Kiniksa, adding: